Monday, September 21, 2026
ExploreSearch
Via News
Markets

Arena Pharmaceuticals Stock Bullish Momentum With A 2.53% Rise On Thursday

ViaNews Editorial Team

December 10, 2020

Arena Pharmaceuticals Stock Bullish Momentum With A 2.53% Rise On Thursday
The Nasdaq Stock Market ended the session with Arena Pharmaceuticals jumping 2.53% to $70.62 on Thursday, following yesterday's downward trend. The Nasdaq Stock Market rose 0.54% to $12,405.80, following yesterday's downward trend on what was a somewhat positive trend exchanging session today. Arena Pharmaceuticals today's close was $70.62, 27.71% under its 52-week high of $90.19.

Arena Pharmaceuticals's Sales

Arena Pharmaceuticals's sales growth is a negative 81.3% for the present quarter and 155.7% for the next. The company's growth estimates for the ongoing quarter is a negative 4.5% and positive 4.5% for the next.

Arena Pharmaceuticals's Revenue

Year-on-year quarterly revenue growth declined by 98.5%, now sitting on 3.28M for the twelve trailing months.

Arena Pharmaceuticals's Stock Top and Bottom Yearly Value

Arena Pharmaceuticals's stock is valued at $70.62 at 17:35 EST, way below its 52-week high of $90.19 and way above its 52-week low of $32.95.

Arena Pharmaceuticals's Moving Average

Arena Pharmaceuticals's value is under its 50-day moving average of $73.43 and higher than its 200-day moving average of $69.02.

Categories

Markets

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNASDAQMarket SessionIXICThe Nasdaq Stock MarketARNAArena PharmaceuticalsStock Price Up
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com